Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1996 Oct;55(10):756–760. doi: 10.1136/ard.55.10.756

Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus.

T Stoll 1, G Stucki 1, J Malik 1, S Pyke 1, D A Isenberg 1
PMCID: PMC1010295  PMID: 8984942

Abstract

OBJECTIVE: To examine the association among the BILAG disease activity index components and their relations with global assessments, health status, and laboratory tests with regard to the validity of the BILAG index. METHODS: A cross sectional study of consecutive patients with systemic lupus erythematosus (SLE) attending a specialist lupus outpatient clinic between July 1994 and February 1995. The internal consistency of the British Isles Lupus Assessment Group (BILAG) index-a disease activity assessment system for SLE patients, based on the principle of the physician's intention to treat-was examined using Cronbach's coefficient alpha. The association of the components of the BILAG index with health status as measured with the MOS Short Form 20 (SF-20), with patients' and doctors' global assessments of patient wellbeing and with laboratory tests was analysed with Spearman rank correlations. RESULTS: 133 female and eight male patients, age 20.1 to 88.7 years (mean 41.1, SD 12.5), were included. With few exceptions, the components of the BILAG index which reflect disease activity in different organ systems were not associated with each other. With the exception of the mucocutaneous component, we found a significant relation between all components of BILAG and global assessment of patient wellbeing, health status, erythrocyte sedimentation rate, or serum C3 level. CONCLUSIONS: The study confirms the validity of all but the mucocutaneous component of the BILAG index. However, disease activity in different organ systems in SLE does not follow a common pattern. Thus the individual BILAG components should be used rather than the total BILAG score as a primary endpoint in clinical and epidemiological studies. To capture the total effect of SLE on an individual measures of disease activity, damage, and health status are all needed.

Full text

PDF
756

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ehrenstein M. R., Longhurst C. M., Latchman D. S., Isenberg D. A. Serological and genetic characterization of a human monoclonal immunoglobulin G anti-DNA idiotype. J Clin Invest. 1994 Apr;93(4):1787–1797. doi: 10.1172/JCI117164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Hay E. M., Bacon P. A., Gordon C., Isenberg D. A., Maddison P., Snaith M. L., Symmons D. P., Viner N., Zoma A. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993 Jul;86(7):447–458. [PubMed] [Google Scholar]
  3. Karlson E. W., Daltroy L. H., Lew R. A., Wright E. A., Partridge A. J., Roberts W. N., Stern S. H., Straaton K. V., Wacholtz M. C., Grosflam J. M. The independence and stability of socioeconomic predictors of morbidity in systemic lupus erythematosus. Arthritis Rheum. 1995 Feb;38(2):267–273. doi: 10.1002/art.1780380217. [DOI] [PubMed] [Google Scholar]
  4. Liang M. H., Socher S. A., Larson M. G., Schur P. H. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989 Sep;32(9):1107–1118. doi: 10.1002/anr.1780320909. [DOI] [PubMed] [Google Scholar]
  5. Lloyd W., Schur P. H. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981 May;60(3):208–217. doi: 10.1097/00005792-198105000-00004. [DOI] [PubMed] [Google Scholar]
  6. Morrow W. J., Isenberg D. A., Todd-Pokropek A., Parry H. F., Snaith M. L. Useful laboratory measurements in the management of systemic lupus erythematosus. Q J Med. 1982 Spring;51(202):125–138. [PubMed] [Google Scholar]
  7. Stewart A. L., Hays R. D., Ware J. E., Jr The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988 Jul;26(7):724–735. doi: 10.1097/00005650-198807000-00007. [DOI] [PubMed] [Google Scholar]
  8. Symmons D. P., Coppock J. S., Bacon P. A., Bresnihan B., Isenberg D. A., Maddison P., McHugh N., Snaith M. L., Zoma A. S. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med. 1988 Nov;69(259):927–937. [PubMed] [Google Scholar]
  9. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  10. Wachtel T., Piette J., Mor V., Stein M., Fleishman J., Carpenter C. Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Intern Med. 1992 Jan 15;116(2):129–137. doi: 10.7326/0003-4819-116-2-129. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES